Safety and anti-HCV effect of prolonged intravenous silibinin in HCV genotype 1 subjects in the immediate liver transplant period

Journal of Hepatology

Volumn 58, Issue 3, 2013, Pages 421-426

  Bárcena, Rafael ^a   Moreno, Ana ^b   Rodríguez Gandía, Miguel Angel ^a   Albillos, Agustín ^a   Arocena, Carlos ^a   Blesa, Carlos ^a   García Hoz, Fernando ^a   Graus, Javier ^a   Nuño, Javier ^c   López Hervás, Pedro ^c   Gajate, Luis ^d   Martínez, Adolfo ^d   Bermejo, Teresa ^e   Mateos, María Luisa ^f   Del Campo, Santos ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b Service of Infectious Diseases   (Spain)

^c Service of General and Digestive Surgery   (Spain)

^d Service of Anesthesiology   (Spain)

^e Services of Pharmacy   (Spain)

^f Service of Microbiology   (Spain)

Author keywords

HCV recurrence; HCV RNA kinetics; Intravenous silibinin; Liver transplantation; Safety

Indexed keywords

ANTIVIRUS AGENT; BASILIXIMAB; MYCOPHENOLIC ACID; SILIBININ; STEROID; TACROLIMUS; VIRUS RNA;

ABSENCE OF SIDE EFFECTS; ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HUMAN; HYPERBILIRUBINEMIA; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; MALE; MONOTHERAPY; PILOT STUDY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; TREATMENT DURATION; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; RNA, VIRAL; SILYMARIN;

EID: 84874105949     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.10.009     Document Type: Article

References (42)

1. G.M. Lauer, and B.D. Walker Hepatitis C virus infection N Engl J Med 345 2001 41 52
2. World Health Organization Hepatitis C; 1999. < http://www.who.int/ immunization/topics/hepatitisc/en/index.htlml/ >.
3. National Institute of Health (NIH) National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 2002 - June 10-12, 2002 Hepatology 36 2002 S3 S20 [PubMed]
4. L.M. Forman, J.D. Lewis, J.A. Berlin, H.I. Feldman, and M.R. Lucey The association between hepatitis C infection and survival after orthotopic liver transplantation Gastroenterology 122 2002 889 896
5. S.K. Satapathy, S. Sclair, M.I. Fiel, J. del Río, and T. Schiano Clinical characterization of patients developing histologically proven fibrosing cholestatic hepatitis C post-liver transplantation Hepatol Res 41 2011 328 339
6. M. Berenguer, M. Prieto, J.M. Rayon, J. Mora, M. Pastor, and V. Ortiz Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation Hepatology 32 2000 852 858
7. X. Forns, M. García-Retortillo, T. Serrano, A. Feliu, F. Suarez, and M. de la Mata Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation J Hepatol 39 2003 389 396
8. J.S. Crippin, T. McCashland, N. Terrault, P. Sheiner, and M.R. Charlton A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation Liver Transpl 8 2002 350 355
9. G.T. Everson, J. Trotter, L. Forman, M. Kugelmas, A. Halprin, and B. Fey Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy Hepatology 42 2005 255 262
10. J.A. Carrión, E. Martínez-Bauer, G. Crespo, S. Ramírez, S. Pérez del Pulgar, and García-Valdecasas Antiviral therapy increases the risk of bacterial infections in HCV infected cirrhotic patients awaiting liver transplantation: a retrospective study J Hepatol 50 2009 719 728
11. A.K. Shergill, M. Khalili, S. Straley, K. Bollinger, J.P. Roberts, and N.A. Ascher Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation Am J Transplant 5 2005 118 124
12. N. Bzowel, D.R. Nelson, N.A. Terrault, G.T. Everson, L.L. Teng, and Prabhakar PHOENIX: a randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus Liver Transpl 17 2011 528 538
13. L. Castells, V. Vargas, H. Allende, I. Bilbao, J. Lázaro, and C. Margarit Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation J Hepatol 43 2005 53 59
14. E. Otón, R. Bárcena, J.M. Moreno-Planas, V. Cuervas-Mons, A. Moreno-Zamora, and C. Barrios Hepatitis C recurrence after liver transplantation: viral and histological response to full-dose peg-interferon and ribavirin Am J Transplant 6 2006 2348 2355
15. M. Berenguer Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin J Hepatol 49 2008 274 287
16. P. Ferenci, T.M. Scherzer, H. Kerschner, K. Rutter, S. Beinhardt, and H. Hofer Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy Gastroenterology 135 2008 1561 1567
17. K. Rutter, T.M. Scherzer, S. Beinhardt, H. Kerschner, A.F. Stättermayer, and H. Hofer Intravenous silibinin as "rescue treatment" for on-treatment non-responders to pegylated interferon/ribavirin combination therapy Antivir Ther 16 2011 1327 1333
18. B.A. Payer, T. Reiberger, K. Rutter, S. Beinhardt, A.F. Stäettermayer, and M. Peck-Radosavjevic Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV-HCV coinfected patient J Clin Virol 49 2010 131 133
19. U.P. Neumann, M. Biermer, D. Eurich, P. Neuhaus, and T. Berg Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy J Hepatol 52 2010 951 954
20. S. Beinhardt, Rasoul-Rockenschaub, T.M. Scherzer, and P. Ferenci Silibinin monotherapy prevents graft infection after orthotopic liver transplantation in a patient with chronic hepatitis C J Hepatol 54 2011 591 592
21. D. Eurich, M. Bahra, T. Berg, S. Boas-Knoop, M. Biermer, and R. Neuhaus Treatment of hepatitis C virus reinfection after liver transplant with silibinin in nonresponders to pegylated interferon-based therapy Exp Clin Transplant 9 2011 1 6
22. J. Wagoner, A. Negash, O.J. Kane, L.E. Martínez, Y. Nahmias, and N. Bourne Multiple effects of silymarin on the hepatitis C virus lifecycle Hepatology 51 2010 1912 1921
23. A. Ahmed-Belkacem, N. Ahnou, L. Barbotte, C. Wychowski, C. Pallier, and R. Brillet Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase Gastroenterology 138 2010 1112 1122
24. J. Guedj, H. Dahari, R.T. Pohl, P. Ferenci, and A.S. Perelson Understanding silibinińs modes of action against HCV using viral kinetic modelling J Hepatol 56 2012 1019 1024
25. T. Fukumoto, T. Berg, Y. Ku, W.O. Bechstein, M. Knoop, and H.P. Lemmens Viral dynamics of hepatitis C early after orthotopic liver transplantation: evidence for rapid turnover of serum virions Hepatology 24 1996 1351 1354
26. M. García-Retortillo, X. Forns, A. Feliu, E. Mointinho, J. Costa, and M. Navasa Hepatitis C virus kinetics during and immediately after liver transplantation Hepatology 35 2002 680 687
27. K.A. Powers, R.M. Ribeiro, K. Patel, S. Pianko, L. Nyberg, and P. Pockros Kinetics of hepatitis C virus reinfection after liver transplantation Liver Transpl 12 2006 207 216
28. H.W. Reesink, S. Zeuzem, C.J. Weegink, N. Forestier, A. van Vliet, and Rooij van de Wetering de Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase 1b placebo controlled randomized study Gastroenterology 131 2006 997 1002
29. I. Yamada, F. Suzuki, N. Kamiya, K. Aoki, Y. Sakurai, and M. Kano Safety pharmacokinetics and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection J Viral Hepatol 19 2012 e-112 e-119
30. C. Sarrazin, R. Rouzier, F. Wagner, N. Forestier, D. Larrey, and S.K. Gupta SCH503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon α-2b for genotype 1 nonresponders Gastroenterology 132 2007 1270 1278
31. P. Halfon, and C. Sarrazin Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important? Liver Int 32 2012 79 87
32. J. Wagoner, C. Morishima, T.N. Graf, N.H. Oberlies, E. Teissier, and E.I. Pécheur Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation PLoS One 6 2011 e16464
33. R. Eren, D. Landstein, D. Terkieltaub, O. Nussbaum, A. Zauberman, and J. Ben-Porath Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients J Virol 80 2006 2654 2664
34. E. Galun, N.A. Terrault, R. Eren, A. Zauberman, O. Nussbaum, and D. Terkieltaub Clinical evaluation (Phase I) of a human monoclonal antibody against hepatitis C virus: safety and antiviral activity J Hepatol 46 2007 37 44
35. T.D. Schiano, M. Charlton, Z. Younossi, E. Galun, T. Pruett, and R. Tur-Kaspa Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a Phase 2 randomized study Liver Transpl 12 2006 1381 1389
36. E. Estrabaud, M. Vidaud, P. Marcellin, and T. Asselah Genomics and HCV infection: progression of fibrosis and treatment response J Hepatol 2012 [Epub ahead of print]
37. J.G. McHutchison, M.P. Manns, A.J. Muir, N.A. Terrault, I.M. Jacobson, N.H. Afdhal For the Telaprevir for previously treated chronic HCV infection N Engl J Med 362 2010 1292 1303
38. B.R. Bacon, S.C. Gordon, E. Lawitz, P. Marcellin, J.M. Vierling, and S. Zeuzem Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
39. M. Charlton Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents-a potentially lethal cocktail Hepatology 54 2011 20 27
40. S. Brillanti, G. Mazzella, and E. Roda Ribavirin for chronic hepatitis C: and the mystery goes on Dig Liver Dis 43 2011 425 430
41. M.K. Jain, and C. Zoellner Role of ribavirin in HCV treatment response: now and in the future Expert Opin Pharmacother 11 2010 673 683
42. M. Biermer, and T. Berg Rapid suppression of hepatitis C viremia induced by intravenous silibinin plus ribavirin Gastroenterology 137 2009 390 396